Research
Hormonal
Recent antiobesity drugs have shown weight loss effects of 12%–17% and can resolve NASH in some patients.
Consider the use of antiobesity medications as part of a comprehensive treatment plan for NASH.
StrongSupportsmedium confidence
Recent antiobesity drugs, including semaglutide or tirzepatide, have shown 12%–17% weight loss effects.
Why this rating
Based on randomized trials referenced in the abstract.
Source
Bariatric surgery the best potential treatment for nonalcoholic fatty liver disease (NAFLD)
Burhanuddin Sohail Rangwala et al. · International Journal of Surgery Global Health · 2023
DOI 10.1097/gh9.0000000000000168
other · n=288
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →